Sintx Technologies (NASDAQ:SINT) vs. LENSAR (NASDAQ:LNSR) Financial Survey

LENSAR (NASDAQ:LNSR) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for LENSAR and Sintx Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	0	0	1	0	3.00
Sintx Technologies	0	1	0	0	2.00

LENSAR presently has a consensus target price of $8.00, suggesting a potential upside of 8.40%. Given LENSAR’s stronger consensus rating and higher probable upside, research analysts clearly believe LENSAR is more favorable than Sintx Technologies.

Profitability

This table compares LENSAR and Sintx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENSAR	-34.03%	-49.02%	-21.12%
Sintx Technologies	-358.79%	-140.68%	-78.29%

Valuation and Earnings

This table compares LENSAR and Sintx Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$48.87 million	1.75	-$14.38 million	($1.46)	-5.05
Sintx Technologies	$2.63 million	2.53	-$8.26 million	($50.56)	-0.10

Sintx Technologies has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 38.5% of LENSAR shares are owned by company insiders. Comparatively, 0.0% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

LENSAR has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Summary

LENSAR beats Sintx Technologies on 10 of the 14 factors compared between the two stocks.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.